Page 103 - Amgen News Today

Explore Boston's vibrant biotech landscape with twelve innovative companies leading the charge in life sciences research.

Tucker Asset Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 669 shares of the medical research company’s stock after buying an additional 88 shares during the […]

Texas Air chief Frank Lorenzo took an airline with no profits and limited prospects and built it into the country’s largest. How? By betting like the sky’s the limit.

Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly

Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce WESTLAKE VILLAGE, Calif., March 11, 2024 -- Arcutis...

Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior...

Overlooked in the biologic era, it still has a place.

On 9 March 2024, Samsung Bioepis presented two papers of study results for its immunology portfolio at the 2024 American Academy of Dermatology (AAD)…

In 2023, the U.S. Supreme Court affirmed invalidity of two Amgen patents based on a lack of enablement for broad genus claims that would potentially encompass millions of antibodies. The Court1...

The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targe...